NeoGenomics detailed its expansion into NGS-based advanced oncology testing, leveraging a broader assay menu and community focus to differentiate in an increasingly crowded segment. Since the start of 2026, the company launched PanTracer Pro for therapy selection in solid tumors and RaDar ST for molecular residual disease monitoring, following earlier product introductions. The company said investor response has been favorable, noting its stock has more than doubled over the past year. NeoGenomics also emphasized RaDar ST sensitivity specifications, citing published limit-of-detection claims as low as 1 part per million and an 11 ppm limit at 95% probability. The move matters for biotech operators in companion diagnostics and lab-developed tests as firms compete on clinical utility, analytical sensitivity, and breadth of offerings across MRD and therapy-selection use cases.